Electromed (ELMD) Investor presentation summary

Company overview and market position

• Focuses on airway management devices, specifically for bronchiectasis and related conditions.

• Headquartered and manufactures in Minnesota, established in 1992, with 186 employees.

• Market cap of $241.1M, with $13.8M in cash and no debt as of 12/31/2025.

• Operates in a large, underpenetrated U.S. market with a $15.1B total addressable opportunity.

• SmartVest® HFCWO technology is supported by clinical outcomes and strong reimbursement.

Financial performance and growth

• Achieved $68.9M in trailing twelve months (TTM) net revenues as of 12/31/2025.

• Maintains high gross margins at 78% and operating margin of 17%.

• Operating income CAGR of 34% from FY21 through Q2 FY2026.

• Net income for TTM ended 12/31/2025 was $9.0M, with diluted EPS of $1.03.

• Outperformed the Russell Medical Equipment Index in gross and operating margins.

Product and clinical impact

• SmartVest® HFCWO therapy reduces hospitalizations, antibiotic use, and improves lung function.

• 95% of patients would recommend SmartVest®; 97% report feeling better or the same.

• Enhanced patient experience with portable, intuitive device and robust reimbursement coverage.

• SmartNotes™ system tracks patient outcomes and supports physician decision-making.